by Dr. C.H. Weaver M. D. 12/2020
The results from the CONTESSA clinical trial evaluating tesetaxel, an orally administered taxane chemotherapy in patients with metastatic breast cancer (MBC), were presented at the December 2020 San Antonio Breast Cancer Symposium. Taxane chemotherapy, a mainstay of treatment for breast cancer is typically administered intravenously as Taxol (paclitaxel) or Taxotere (docetaxel). The availability of an orally administered taxane for the treatment of MBC could offer convenience and improved quality of life for individuals facing a diagnosis of advanced breast cancer.
The CONTESSA clinical trial directly compared orally administered tesetaxel in combination with Xeloda (capecitabine) to Xeloda alone in 685 patients with recurrent hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative MBC. All patients had been previously treated with a taxane for early-stage breast cancer in the neoadjuvant or adjuvant setting. Xeloda is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC.
The combination of tesetaxel plus Xeloda was found to improve the response to treatment and delay cancer progression compared to treatment with Xeloda alone. Overall, 57% of patients responded to treatment with tesetaxel plus Xeloda compared to 41% for Xeloda alone and patients survived 9.8 months without cancer progression compared to 6.9 months for Xeloda. The availability of an orally administered taxane for the treatment of MBC would be a welcome convenient treatment option for individuals facing a diagnosis of advanced breast cancer.
FDA - Breast Implants Linked to Development of Anaplastic Lymphoma
Breast implants associated with risk of rare lymphoma cancer
- Keep Current With The Breast Cancer Community Newsletter
- Connect With Others In The Breast Cancer Community To Share Information And Support